동아에스티
170900KOSPI의약품 제조업46.0 / 100
Reference Date: 2026-06-10
Company InformationBased on 2025 Annual Report
Business Overview
Dong-A ST, established in 2013 through a spin-off from Dong-A Pharmaceutical, focuses on manufacturing and selling specialty pharmaceuticals, medical devices, and pharmaceutical cosmetics. Key products include Grotrixin, Motiriton, and Suganon, with 2024 sales reaching 697.9 billion won, a 5.1% increase from the previous year. Growth was driven by the biopharmaceutical product Grotrixin and increased overseas exports.
Number of Employees
1,685people
Average Salary
78.9M KRW
Score Calculation Basis
Detailed Financial Score
Lower than industry avg (good)
Well below industry avg
4.0x industry avg (risky)
Avg ▲10.5% (2-year basis)
Avg ▼110.6% (2-year basis)
Avg ROE -2.8% (declining, 3yr)
Detailed News Sentiment
- Positive54일 만에 체중 9.1% 감소…동아ST 비만약 후보 주목
동아에스티의 비만 치료제 DA-1726 임상 결과 발표로 긍정적인 시장 반응 예상.
- Positive동아에스티-메타비아, ADA서 비만·MASH 치료제 연구 결과 발표
동아시아스티와 메타비아가 ADA에서 비만 및 대사이상 지방간염 치료제 연구 결과를 발표하며 긍정적인 시장 반응 기대.
- Positive홍종호 국전 대표 “원료의약품서 AI반도체 패키징 등 첨단소재 사업.....
국전 대표의 발언으로 동아에스티의 첨단 소재 사업 확장 기대감 증가.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -14.07% (falling)
Volume flat
Detailed Disclosure
- Neutral지속가능경영보고서등관련사항(자율공시)2026-06-05
- Neutral기업지배구조보고서공시2026-06-01
- Neutral분기보고서 (2026.03)2026-05-15
